Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy

BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Martina, Catalano, Winchler, Costanza, De Gennaro Aquino, Irene, Papa, Francesca, Buttitta, Eleonora, Rossi, Gemma, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613139/
https://www.ncbi.nlm.nih.gov/pubmed/36109437
http://dx.doi.org/10.1007/s12029-022-00865-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613139/
https://www.ncbi.nlm.nih.gov/pubmed/36109437
http://dx.doi.org/10.1007/s12029-022-00865-5

Ejemplares similares